What is SciSparc Ltd. (SPRC) stock price today?

SciSparc Ltd. (SPRC) is currently trading at $4.44, up 0.18% today.

What is SPRC P/E ratio?

SciSparc Ltd.'s P/E ratio is -0.02. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SPRC return on equity (ROE)?

SciSparc Ltd.'s return on equity (ROE) is -704.60%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is SciSparc Ltd.'s market cap?

SciSparc Ltd. has a market capitalization of $256684.

NASDAQ · Biotechnology

SciSparc Ltd. (SPRC) Stock

$4.44 +0.18% NASDAQ: SPRC Healthcare

Valuation

Metric	Value
Price	$4.44
Market Cap	$256684
P/E Ratio	-0.02
P/B Ratio	0.05
P/S Ratio	0.32
EPS (TTM)	$0.00
52-Week High	$48.33
52-Week Low	$2.98
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-704.60%
ROA	-159.79%
ROCE	-162.95%
Gross Margin	-900.00%
Operating Margin	-900.00%
Net Margin	-14.23%
Debt/Equity	0.09
Current Ratio	2.50

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$1.0M	$3.0M	$1.0M	$1.0M
Operating Profit	$-6.0M	$-7.0M	$-6.0M	$-7.0M	$-9.0M
Net Profit	$-6.0M	$-3.0M	$-5.0M	$-6.0M	$-12.0M
EPS	$-3311.10	$-666.90	$-649.35	$-9.72	$-882.64
Op Margin	-539.6%	-547.9%	-200.5%	-560.2%	-1022.1%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$10.0M	$11.0M	$11.0M	$10.0M	$8.0M
Total Liabilities	$2.0M	$4.0M	$2.0M	$1.0M	$2.0M
Cash	$7.0M	$4.0M	$2.0M	$2.0M	$5.0M
Borrowings	$1.0M	$0	$0	$0	$0

Latest News

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome NewMediaWire · Jul 15, 2026 SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome GlobeNewswire · Jul 15, 2026 SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum GlobeNewswire · Jun 4, 2026 NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd. NewMediaWire · Jun 3, 2026 SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-5.0M	$-8.0M	$-6.0M	$-5.0M	$-4.0M
Investing Cash Flow	$0	$-12.0M	$-1.0M	$-2.0M	$-1.0M
Financing Cash Flow	$0	$3.0M	$0	$0	$0
Net Cash Flow	$5.0M	$-3.0M	$-1.0M	$-1.0M	$3.0M
Free Cash Flow	$-5.0M	$-13.0M	$-6.0M	$-5.0M	$-4.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.46
FCF Yield	-1515.38%
Quick Ratio	2.38
Interest Coverage	-1.07
Return 1Y	-92.43%
Return 3Y	-99.82%
Return 5Y	—

Ownership

Insiders Held0.00%

Institutions Held0.55%

Institutions Float Held0.55%

Institutional Holder	Shares	Report Date
UBS Group AG	3,146	2026-03-31
SBI Securities Co., Ltd.	1	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ARTLArtelo Biosciences, Inc.	$3.37	-1.17%	-0.05	$1.31M	0.00%
AZTRAzitra Inc	$0.13	-1.74%	-0.10	$1.39M	0.00%
INDPIndaptus Therapeutics, Inc.	$2.53	+6.54%	-0.34	$285.94M	0.00%
JSPRJasper Therapeutics, Inc.	$0.57	+1.13%	-0.36	$9.20M	0.00%
LIPOLipella Pharmaceuticals Inc.	$0.07	+0.00%	-0.05	$300354	0.00%

About SciSparc Ltd.

SciSparc Ltd. is led by CEO Oz Adler, employs 2 people, headquartered in IL, publicly traded since 2021.

SciSparc Ltd. (SPRC) stock trades at $4.44 with a market capitalization of $256684. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.05, price-to-sales of 0.32. Over the past 52 weeks the stock has ranged between $2.98 and $48.33, and currently trades 90.8% below its 52-week high.

On profitability, SciSparc Ltd. generates a return on equity (ROE) of -704.60%, return on capital employed of -162.95%, an operating margin of -900.00%, a net profit margin of -14.23%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.40 -0.02% JNJ Johnson & Johnson $259.67 +1.24% ABBV AbbVie Inc. $275.32 +1.06% MRK Merck & Company, Inc. Common Stock (new) $144.97 +1.82% UNH UnitedHealth Group Incorporated Common Stock (DE) $374.45 +0.94% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $656.26 +0.66% AMGN Amgen Inc. $410.68 +0.80% GILD Gilead Sciences, Inc. $149.76 +1.81% ABT Abbott Laboratories $99.62 +1.15% NVO Novo Nordisk A/S $38.39 +0.54%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides